DOCSLIB.ORG

Interleukin 6 Inhibits Mouse Placental Lactogen II but Not Mouse Placental Lactogen I Secretion in Vitro (Trophoblast/Pregnancy/Cytokine) M

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Interleukin 6 Inhibits Mouse Placental Lactogen II but Not Mouse Placental Lactogen I Secretion in Vitro (Trophoblast/Pregnancy/Cytokine) M Proc. Natl. Acad. Sci. USA Vol. 90, pp. 11905-11909, December 1993 Physiology Interleukin 6 inhibits mouse placental lactogen II but not mouse placental lactogen I secretion in vitro (trophoblast/pregnancy/cytokine) M. YAMAGUCHI*t, L. OGREN*, J. N. SOUTHARD*, H. KURACHI*, A. MIYAKEt, AND F. TALAMANTES*§ *Department of Biology, University of California, Santa Cruz, CA 95064; and tDepartment of Obstetrics and Gynecology, Osaka University Medical School, Osaka, Japan 565 Communicated by George E. Seidel, Jr., September 7, 1993 (receivedfor review June 9, 1993) ABSTRACT The mouse placenta produces several poly- members ofthe PRL-GH gene family. We have used primary peptides belonging to the prolactin-growth hormone gene fam- cultures of placental cells from several days of pregnancy to ily, including mouse placental lactogen (mPL) I and mPL-II. demonstrate that IL-6 regulates the secretion of mPL-II, but The present study was undertaken to determine whether the not mPL-I, and that the sensitivity of mPL-II secretion to secretion of mPL-I and mPL-H is regulated by interleukin 6 IL-6 varies during gestation. (IL-6), which is present in the placenta and has previously been reported to stimulate the secretion ofpituitary members of this gene family. Effects of human and mouse IL-6 on mPL-I and MATERIALS AND METHODS mPL-II secretion were examined in primary cultures of pla- Hormones, Cytokines, and Antisera. mPL-II and recombi- cental cells from days 7, 9, and 12 of pregnancy. IL-6 caused nant mPL-I were purified as described (10, 16). Rabbit a dose-dependent reduction in the mPL-HI concentration in the anti-mPL-I and rabbit anti-mPL-II antisera have been de- medium of cells from days 9 and 12 of pregnancy but did not scribed (11, 16). Recombinant human IL-6 (hIL-6) was a gift affect the mPL-II concentration in the medium ofcells from day from Toshio Hirano and Tadamitsu Kishimoto (Osaka Uni- 7 of pregnancy or the mPL-I concentration in the medium of versity). Recombinant mouse IL-6 (mIL-6) and goat anti- cells from days 7 or 9 of pregnancy. The lowest concentration mIL-6 antiserum were purchased from R & D Systems. of human IL-6 that significantly inhibited mPL-II secretion Cell Dissociation and Culture. Conceptuses were collected was 250 pM. The effect of IL-6 on the mPL-II concentration in from timed-pregnant Swiss Webster mice (Simonsen Labo- the medium was due primarily to inhibition of mPL-II synthe- ratories, Gilroy, CA) on days 7, 9, and 12 of pregnancy sis, which resulted at least partly from a decrease in the (vaginal plug on day 0). The fetus and decidua basalis were steady-state level of mPL-II mRNA. These data raise the discarded from conceptuses from days 7 and 9 of pregnancy, possibility that IL-6 may regulate mPL-I production after and the remaining tissue was dispersed. The labyrinth and midpregnancy in vivo. basal zone were used from conceptuses from day 12 of pregnancy. Cell preparations contained tissue from 130 con- The role of interleukin 6 (IL-6) in regulating the immune ceptuses from day 7 of pregnancy or 65 conceptuses from response and hematopoiesis has been investigated exten- days 9 or 12 of pregnancy. The tissue was dispersed in sively and is well established (1). Recent studies have sug- collagenase, and the cells were fractionated on a Percoll gested that IL-6 is also involved in regulating the function of gradient as described (23). Cells banding at a density of 1.044 several endocrine organs, including the pituitary gland (2, 3) g/ml were suspended in culture medium [NCTC-135 supple- and placenta (4-6). In the rat pituitary gland, IL-6 stimulates the secretion offollicle-stimulating hormone, luteinizing hor- mented with 10 mM Hepes, 25 mM NaHCO3, 1.65 mM mone, prolactin (PRL), and growth hormone (GH) (2, 3). In cysteine, streptomycin (50 ,ug/ml), and penicillin G (50 the human placenta, it stimulates the secretion of human units/ml)] containing 5% (vol/vol) fetal bovine serum. This chorionic gonadotropin (4-6), which is structurally and func- cell population has been shown (24, 25) to contain trophoblast tionally very similar to luteinizing hormone. giant cells that produce mPL-I and mPL-II. The cells were The placentas of numerous species produce proteins that plated at a density of 2.0-3.0 x 105 cells per cm2 in plastic are members ofthe PRL-GH gene family (for review, see ref. multiwell plates and incubated at 37°C in 95% air/5% CO2. 7). In the mouse, two ofthe placental members ofthis family Two hours after plating, the medium was replaced with are mouse placental lactogen (mPL) I and mPL-II. mPL-I is culture medium without fetal bovine serum. IL-6 was added a 29- to 42-kDa glycoprotein that is present at high concen- to the cultures at this time. In experiments in which IL-6 was tration in the maternal blood between days 8 and 11 of neutralized by pretreatment with anti-IL-6 antibodies, 250 pregnancy (8, 9). mPL-II is a nonglycosylated 22-kDa poly- pM mIL-6 was incubated with goat anti-mIL-6 IgG at 20 peptide that appears in the maternal blood on day 9 of pug/ml for 1 hr at 37°C immediately before addition to the pregnancy. Its concentration increases for several days and cultures. Control cultures in the neutralization experiment then levels offin some strains ofmice or continues to increase were treated with the same concentration of IL-6 that had for the remainder ofpregnancy in others (10-13). The known been incubated with nonimmune goat IgG at 20 pg/ml. The functions ofboth mPLs are like those ofPRL. They stimulate medium was changed daily in all experiments, and cultures mammary gland functional differentiation (14-16) and play a were continued for up to 5 days. role in regulating ovarian steroidogenesis (17). Western Blot Analysis. Western blot analysis was carried Since IL-6 was recently identified in mouse blastocysts, out as described (8) with minor modifications. Briefly, sam- placenta, and uterus (18-22), it was of interest to determine whether this cytokine affects the production of placental Abbreviations: GH, growth hormone; IL-6, interleukin 6; mIL-6, mouse IL-6; hIL-6, human IL-6; mPL, mouse placental lactogen; PRL, prolactin; EGF, epidermal growth factor. The publication costs of this article were defrayed in part by page charge tPresent address: Department of Obstetrics and Gynecology, Osaka payment. This article must therefore be hereby marked "advertisement" University Medical School, Osaka, Japan 565. in accordance with 18 U.S.C. §1734 solely to indicate this fact. §To whom reprint requests should be addressed. 11905 Downloaded by guest on September 30, 2021 11906 Physiology: Yamaguchi et al. Proc. Natl. Acad Sci. USA 90 (1993) 140 ples were subjected to electrophoresis on 12% polyacryl- -A amide gels in the presence of SDS under reducing conditions, 120 and the proteins were transferred to a nitrocellulose mem- brane. The membranes were washed, blocked, and then 100 with rabbit anti-mPL-II antiserum (1:200 dilution). incubated 80 Proteins bound to anti-mPL-II antiserum were visualized by incubating the membranes with 1251-labeled anti-rabbit IgG 60 solution (0.5,uCi/ml; 1 Ci = 37 GBq), followed by autorad- iography using Kodak XAR5 x-ray fim. The autoradiographs 6 40 were scanned with a Bio-Rad model 620 video densitometer. 20 Band intensities were determined with ID ANALYST (Version 3.10) software from Bio-Rad. The specificity of the method 0 was established by replacing the primary antiserum with 0 1 2 3 4 5 nonimmune serum. Recombinant mPL-II was used as a Day of Culture positive control. 120 B Northern Blot Analysis. Cells were seeded into 6-well plates at a density of 3 x 106 cells per well. The cells were harvested 100 with a rubber policeman, and total RNA was prepared by the acid guanidinium thiocyanate/phenol/chloroform method 80 (26). All of the RNA from each well was separated on a 1.5% agarose/formaldehyde gel and transferred to a Nytran mem- X 60 brane (Schleicher & Schuell) (27). 32P-labeled mPL-II cDNA (28) and human ribosomal protein L7 cDNA (27) probes were 40 generated with the Multiprime kit (Amersham). Hybridiza- tions were carried out as described (27). Autoradiography 20 and the analysis of the autoradiographs were carried out as described for Western blot analysis. The intensity of the 0 , mPL-II mRNA band in each lane was normalized to that of 0 1 2 3 4 5 the L7 band to control for differences in sample loading and Day of Culture transfer efficiency between lanes. Protein Synthesis. De novo synthesis of trichloroacetic FIG. 1. Time course of mPL-I secretion by cells from days 7(A) acid-precipitable proteins in the cells and medium was as- and 9(B) of pregnancy in the absence (e) and presence (o) of 2.5 nM hIL-6. Cells were plated at 105 cells per well in 96-well plates and sessed by incubating the cells with 50 ,uCi of [3H]leucine cultured for 5 days. The medium was changed daily and assayed for between 118 and 120 hr of culture as described (25). Intra- mPL-I concentration by RIA. Each value represents the mean ± cellular proteins were extracted with 0.5% Triton X-100. SEM of six wells. There was no difference in the mPL-I concentra- Radnoimmunoassays and DNA Assay. mPL-I and mPL-II tion of the medium between hIL-6-treated and control cells on either concentrations were determined as described (9, 11).
Load more

Recommended publications
  • Therapeutic Approaches to Preserve Islet Mass in Type 2 Diabetes
    24 Dec 2005 16:24 AR ANRV262-ME57-17.tex XMLPublishSM(2004/02/24) P1: OJO 10.1146/annurev.med.57.110104.115624 Annu. Rev. Med. 2006. 57:265–81 doi: 10.1146/annurev.med.57.110104.115624 Copyright c 2006 by Annual Reviews. All rights reserved THERAPEUTIC APPROACHES TO PRESERVE ISLET MASS IN TYPE 2DIABETES Laurie L. Baggio and Daniel J. Drucker Department of Medicine, Toronto General Hospital, Banting and Best Diabetes Center, University of Toronto, Toronto, Ontario, Canada M5S 2S2; email: [email protected] KeyWords β-cell mass, apoptosis, neogenesis, proliferation ■ Abstract Type 2 diabetes is characterized by hyperglycemia resulting from in- sulin resistance in the setting of inadequate β-cell compensation. Currently available therapeutic agents lower blood glucose through multiple mechanisms but do not directly reverse the decline in β-cell mass. Glucagon-like peptide-1 (GLP-1) receptor agonists, exemplified by Exenatide (exendin-4), not only acutely lower blood glucose but also engage signaling pathways in the islet β-cell that lead to stimulation of β-cell repli- cation and inhibition of β-cell apoptosis. Similarly, glucose-dependent insulinotropic polypeptide (GIP) receptor activation stimulates insulin secretion, enhances β-cell proliferation, and reduces apoptosis. Moreover, potentiation of the endogenous post- prandial levels of GLP-1 and GIP via inhibition of dipeptidyl peptidase-IV (DPP-IV) also expands β-cell mass via related mechanisms. The thiazolidinediones (TZDs) en- hance insulin sensitivity, reduce blood glucose levels, and also preserve β-cell mass, although it remains unclear whether TZDs affect β-cell mass via direct mechanisms. Complementary approaches to regeneration of β-cell mass involve combinations of factors, exemplified by epidermal growth factor and gastrin, which promote islet neo- genesis and ameliorate diabetes in rodent studies.
    [Show full text]
  • Placental Growth Hormone-Related Proteins and Prolactin-Related Proteins
    Placental Growth Hormone-Related Proteins and Prolactin-Related Proteins The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Haig, D. 2008. Placental growth hormone-related proteins and prolactin-related proteins. Placenta 29: 36-41. Published Version doi:10.1016/j.placenta.2007.09.010 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11148777 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Placental growth hormone-related proteins and prolactin-related proteins. David Haig Department of Organismic and Evolutionary Biology, Harvard University, 26 Oxford Street, Cambridge MA 02138. e-mail: [email protected] phone: 617-496-5125 fax: 617-495-5667 Keywords: GH, PRL, placenta, endometrial glands, placental lactogen The placentas of ruminants and muroid rodents express prolactin (PRL)-related genes whereas the placentas of anthropoid primates express growth hormone (GH)-related genes. The evolution of placental expression is associated with acclerated evolution of the corresponding pituitary hormone and destabilization of conserved endocrine systems. In particular, placental hormones often evolve novel interactions with new receptors. The adaptive functions of some placental hormones may be revealed only under conditions of physiological stress. Introduction Placental hormones are produced by offspring, but act on receptors of mothers. As such, placental hormones and maternal receptors are prime candidates for the expression of parent-offspring conflict [1,2].
    [Show full text]
  • The Importance of Determining Human
    JMB 2009; 28 (2) DOI: 10.2478/v10011-009-0003-1 UDK 577.1 : 61 ISSN 1452-8258 JMB 28: 97–100, 2009 Original paper Originalni nau~ni rad THE IMPORTANCE OF DETERMINING HUMAN PLACENTAL LACTOGEN IN THE THIRD TRIMESTER OF PREGNANCY ZNA^AJ ODRE\IVANJA HUMANOG PLACENTALNOG LAKTOGENA U TRE]EM TRIMESTRU TRUDNO]E Jasmina Durkovi}1, Bojana Mandi}2 1Department of Genetics , Town Hospital, Subotica, Serbia 2Mega Lab, Biochemical Laboratory, Subotica, Serbia Summary: Human placental lactogen (HPL) is a hormone Kratak sadr`aj: Humani placentalni laktogen (HPL) jeste produced by the placenta with a role in the re gu lation of hormon koji izlu~uje placenta i regulator je fetoplacen- fetoplacental growth. In this paper, the results of HPL de- talnog rasta. U radu su prikazani rezultati odre|ivanja HPL- termination in the third trimester of pregnancy are pre- a u tre}em trimestru trudno}e, sa ciljem da se ispita senzi - sented with the aim of testing the sensitivity of this bio - tivnost tog biohemijskog markera za otkrivanje poreme}aja chemical marker for detecting placental dysfunction, fetal funkcije placente, vitaliteta fetusa i rizika za lo{ ishod. vitality and risk of bad outcome. The tests were performed Ispitivanje je obavljeno na uzorku od 370 rizi~nih trudno}a on 370 women with high-risk pregnancy, between the 20th izme|u 20 i 36 nedelje trudno}e. HPL je odre|en ELISA and 36th week of pregnancy. HPL was determined by an metodom, testovima »Bioserv Diagnostics«, a rezultati su ELISA method using Bioserv Diagnostics tests and the o~itani na rideru »STAT–FAX 303+«.
    [Show full text]
  • The Endocrine Function of the Placenta: Interactions Between Trophic Peptides and Hormones
    Placenlal Function and Fetal Nutrition, edited by Frederick C. Battaglia, Nestle Nutrition Workshop Series. Vol. 39. Nestec Ltd.. Vevey/Lippincott-Raven Publishers. Philadelphia. © 1997. The Endocrine Function of the Placenta: Interactions Between Trophic Peptides and Hormones Lise Cedard U. 361 INSERM, Maternite Baudelocque, 121 Boulevard de Port-Royal Paris, France The placenta is classically considered to be a source of hormones that play an important role in the establishment and maintenance of pregnancy. Because of its hemochorial structure, the human placenta produces hormones and easily secretes them into the maternal circulation. They include steroid hormones, such as estrogens and progesterone, and protein hormones, the most important of which are the chori- onic gonadotrophins (hCG), discovered in 1927. During the period from 1960 to 1980, the concept of a fetoplacental unit (1) with a complementary role for the fetus in steroid production offered a new approach to steroid metabolism, and since then new proteins and neuropeptides have been discovered (2,3). However, the lack of innervation of placental tissue highlights the importance of understanding neuroen- docrine regulation of placental physiology. Sophisticated culture methods enabling the study of biologic phenomena occurring during transformation of cytotrophoblast cells into a syncytiotrophoblast (4) have been combined with electron microscopy and histochemistry. Possibilities offered by molecular biology, including in situ hybridization and molecular cloning studies,
    [Show full text]
  • Hormonal Regulation of Fetal Growth
    Inrntuterine Growth Reianlaliim, edited by Jacques Senterre. Nestle Nutrition Workshop Scries, Vol. 18. Nestec Ltd.. Vevey/Raven Press. Ltd., New York © 1989. Hormonal Regulation of Fetal Growth Jean Girard Centre de Recherche sur la Nutrition (CNRS), 92190 Meudon-Bellevue, France The regulation of fetal growth is complex and still very poorly understood. It in- volves genetic factors, maternal nutrition and cardiovascular adaptations, placental growth and function, and to a lesser extent fetal factors, including fetal hormones. The influence of genetic, maternal, and placental factors on fetal growth has been reviewed recently (1) and will not be discussed. The purpose of this chapter is to analyze the specific role of endocrine factors in the determination of fetal growth, assuming that the nutritional supply to the placenta and to the fetus remains un- altered. The major endocrine factors involved in postnatal growth are: (a) growth hor- mone (GH) via the secretion of somatomedin; (b) thyroid hormones; (c) cortisol; and (d) sex steroids at puberty (2,3). Insulin is considered to have a merely permis- sive role in postnatal growth (2,3). In recent years, a body of evidence has accumu- lated to indicate that the fetus may be less dependent on pituitary and thyroid hormones for growth than the older organism, and more dependent on insulin and tissue growth factors. Studies on the endocrine regulation of fetal growth have in- volved several major approaches: ablation of fetal endocrine glands; examination of newborns with congenital endocrine deficiencies; treatment of fetuses with hor- mones; measurement of plasma hormone concentrations and tissue receptor levels during normal or abnormal growth; and in vitro studies of hormone effects on fetal tissues.
    [Show full text]
  • A Role for Placental Kisspeptin in Β Cell Adaptation to Pregnancy
    A role for placental kisspeptin in β cell adaptation to pregnancy James E. Bowe, … , Stephanie A. Amiel, Peter M. Jones JCI Insight. 2019;4(20):e124540. https://doi.org/10.1172/jci.insight.124540. Research Article Endocrinology Reproductive biology During pregnancy the maternal pancreatic islets of Langerhans undergo adaptive changes to compensate for gestational insulin resistance. Kisspeptin has been shown to stimulate insulin release, through its receptor, GPR54. The placenta releases high levels of kisspeptin into the maternal circulation, suggesting a role in modulating the islet adaptation to pregnancy. In the present study we show that pharmacological blockade of endogenous kisspeptin in pregnant mice resulted in impaired glucose homeostasis. This glucose intolerance was due to a reduced insulin response to glucose as opposed to any effect on insulin sensitivity. A β cell–specific GPR54-knockdown mouse line was found to exhibit glucose intolerance during pregnancy, with no phenotype observed outside of pregnancy. Furthermore, in pregnant women circulating kisspeptin levels significantly correlated with insulin responses to oral glucose challenge and were significantly lower in women with gestational diabetes (GDM) compared with those without GDM. Thus, kisspeptin represents a placental signal that plays a physiological role in the islet adaptation to pregnancy, maintaining maternal glucose homeostasis by acting through the β cell GPR54 receptor. Our data suggest reduced placental kisspeptin production, with consequent impaired kisspeptin-dependent β cell compensation, may be a factor in the development of GDM in humans. Find the latest version: https://jci.me/124540/pdf RESEARCH ARTICLE A role for placental kisspeptin in β cell adaptation to pregnancy James E.
    [Show full text]
  • Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases
    nutrients Review Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases João V. S. Guerra 1,2,† , Marieli M. G. Dias 1,3,† , Anna J. V. C. Brilhante 3,4, Maiara F. Terra 1,3, Marta García-Arévalo 1,* and Ana Carolina M. Figueira 1,* 1 Brazilian Center for Research in Energy and Materials (CNPEM), Brazilian Biosciences National Laboratory (LNBio), Polo II de Alta Tecnologia—R. Giuseppe Máximo Scolfaro, Campinas 13083-100, Brazil; [email protected] (J.V.S.G.); [email protected] (M.M.G.D.); [email protected] (M.F.T.) 2 Graduate Program in Pharmaceutical Sciences, Faculty Pharmaceutical Sciences, University of Campinas, Campinas 13083-970, Brazil 3 Graduate Program in Functional and Molecular Biology, Institute of Biology, State University of Campinas (Unicamp), Campinas 13083-970, Brazil; [email protected] 4 Brazilian Center for Research in Energy and Materials (CNPEM), Brazilian Biorenewables National Laboratory (LNBR), Polo II de Alta Tecnologia—R. Giuseppe Máximo Scolfaro, Campinas 13083-100, Brazil * Correspondence: [email protected] or [email protected] (M.G.-A.); ana.fi[email protected] (A.C.M.F.) † Both authors contributed equally to this work. Abstract: Throughout the 20th and 21st centuries, the incidence of non-communicable diseases (NCDs), also known as chronic diseases, has been increasing worldwide. Changes in dietary and physical activity patterns, along with genetic conditions, are the main factors that modulate the Citation: Guerra, J.V.S.; Dias, metabolism of individuals, leading to the development of NCDs. Obesity, diabetes, metabolic M.M.G.; Brilhante, A.J.V.C.; Terra, associated fatty liver disease (MAFLD), and cardiovascular diseases (CVDs) are classified in this M.F.; García-Arévalo, M.; Figueira, group of chronic diseases.
    [Show full text]
  • Preoptic Inputs and Mechanisms That Regulate Maternal Responsiveness
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Repository of the Academy's Library Received Date : 14-Jan-2014 Revised Date : 21-Jul-2014 Accepted Date : 22-Jul-2014 Article type : Review Article Preoptic inputs and mechanisms that regulate maternal responsiveness A. Dobolyi1,2, D.R. Grattan3, D. S. Stolzenberg4 1Laboratory of Molecular and Systems Neurobiology, Institute of Biology, NAP-Hungarian Academy of Sciences and Eötvös Loránd University, Budapest, Hungary 2Laboratory of Neuromorphology, Department of Anatomy, Histology and Embryology, Article Semmelweis University, Budapest, Hungary 3Department of Anatomy and Centre for Neuroendocrinology, School of Medical Sciences, University of Otago, Dunedin, New Zealand 4Department of Psychology, University of California, David CA, USA Corresponding Authors: Prof. Arpad Dobolyi, Laboratory of Molecular and Systems Neurobiology, Institute of Biology, Eötvös Loránd University, Pázmány Péter sétány 1C, Budapest 1117, Hungary email: [email protected] Danielle S. Stolzenberg, Department of Psychology, 135 Young Hall, University of California Davis, CA 95616, USA Email: [email protected] Short title: Preoptic mechanisms of maternal responsiveness Key words: maternal motivation, and maternal behaviour, medial preoptic area of hypothalamus, epigenetics, postpartum period This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to Accepted differences between this version and the Version of Record. Please cite this article as doi: 10.1111/jne.12185 This article is protected by copyright. All rights reserved. Abstract The preoptic area is a well-established centre for the control of maternal behaviour.
    [Show full text]
  • Human Placental Lactogen Administration in the Pregnant Rat: Acceleration of Fetal Growth
    003 1-399818812406-0663$02.00/0 PEDIATRIC RESEARCH Vol. 24, No. 6, 1988 Copyright O 1988 International Pediatric Research Foundation, Inc. Printed in U.S.A. Human Placental Lactogen Administration in the Pregnant Rat: Acceleration of Fetal Growth JAMES W. COLLINS, JR., SANDRA L. FINLEY, DANIEL MERRICK, AND EDWARD S. OGATA Departments of Pediatrics, Obstetrics and Gynecology, Northwestern University Medical School and Prentice Women's Hospital of Northwestern Memorial Hospital and Children's Memorial Hospital, Chicago, Illinois 60611 ABSTRACT. To determine whether administration of hu- servations suggest that placental lactogen may also directly stim- man placental lactogen (hPL) to pregnant rats during late ulate fetal growth. Ovine placental lactogen stimulates glycoge- gestation might enhance fetal growth, we implanted os- nesis in hepatocytes of the fetal rat (4) and sheep (5) and motically driven minipumps to provide 75 pg h PL/24 h on aminoisobutyric acid uptake in diaphragmatic muscle of the fetal day 14 of the rat's 21.5-day gestation. This substantially rat (6). It also stimulates ornithine decarboxylase activity in fetal increased maternal and fetal plasma hPL concentrations. rat liver (7) and somatomedin secretion in fetal and adult tissue By day 18, hPL fetuses were significantly heavier and had (8-10). Handwerger (11) has suggested that these and other larger placentas than controls. From this point until term, observations indicate a critical role for placental lactogen in not their rate of growth (1.20 g/24 h) significantly exceeded only indirectly but also directly stimulating normal fetal growth that of controls (0.95 g/24 h).
    [Show full text]
  • Placental Lactogen-I (PL-I) Target Tissues Identified with an Alkaline Phosphatase–PL-I Fusion Protein
    Volume 46(6): 737–743, 1998 The Journal of Histochemistry & Cytochemistry http://www.jhc.org ARTICLE Placental Lactogen-I (PL-I) Target Tissues Identified with an Alkaline Phosphatase–PL-I Fusion Protein Heiner Müller,1 Guoli Dai, and Michael J. Soares Department of Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City, Kansas SUMMARY The rat placenta expresses a family of genes related to prolactin (PRL). Target tissues and physiological roles for many members of the PRL family have yet to be deter- mined. In this investigation we evaluated the use of an alkaline phosphatase (AP) tag for monitoring the behavior of a prototypical member of the PRL family, placental lactogen-I (PL-I). A probe was generated consisting of a fusion protein of human placental AP and rat KEY WORDS PL-I (AP–PL-I). The AP–PL-I construct was stably expressed in 293 human fetal kidney cells, as alkaline phosphatase fusion was the unmodified AP vector that served as a control. AP activity was monitored with a protein colorimetric assay in conditioned medium from transfected cells. Immunoreactivity and ovary, corpus luteum prolactin PRL-like biological activities of the AP–PL-I fusion protein were demonstrated by immuno- receptors blotting and the Nb2 lymphoma cell proliferation assay, respectively. AP–PL-I specifically liver, hepatic prolactin bound to tissue sections known to express the PRL receptor, including the ovary, liver, and receptors choroid plexus. Binding of AP–PL-I to tissues was specific and could be competed with ovine Nb2 lymphoma cells PRL. The results indicate that AP is an effective tag for monitoring the behavior of PL-I and placental lactogen-I suggest that this labeling system may also be useful for monitoring the actions of other pregnancy members of the PRL family.
    [Show full text]
  • Hormones Steroids Antibodies
    Fitzgerald Industries International is the premier provider of over 45,000 highly purified Monoclonal and Polyclonal Antibodies, purified Proteins, ELISA Kits and Specialty Research Products. For more than 20 years our customers have known that they can depend on Fitzgerald Industries to supply them with high quality products for research and further manufacture. Hormones and their receptors play a central role in the regulation of gene expression. These soluble receptors, when bound to their corresponding hormone, regulate gene expression through direct interaction with promoter response elements. Fitzgerald Industries offers a wide selection of tools that can be used to investigate the function of hormones and their receptors, and our current brochure encompasses over 800 antibodies and purified hormones and steroids spanning a vast range of targets including steroid hormones such as Glucocorticoids, Estrogens, Androgens; small peptide hormones such as TRH and vasopressin; protein hormones such as insulin and growth hormones; and glycoprotein hormones such as LH, TSH, and FSH. In addition, we offer comprehensive listings in other research areas including Cancer, Cell Biology, Immunology, Infectious Disease, Signal Transduction, Neuroscience, Cytokines & Growth Factors, Cardiac Markers, Protein Modification, Cell Death & Stress, and many more. Visit our website at www.fitzgerald-fii.com to view our complete offerings and full technical data. www.fitzgerald-fii.com/Hormones & Steroids Hormones & Steroids 1 Fitzgerald Industries International
    [Show full text]
  • Apolipoproteins AI, AII, and CI Stimulate Placental Lactogen Release from Human Placental Tissue. a Novel Action of High Density Lipoprotein Apolipoproteins
    Apolipoproteins AI, AII, and CI stimulate placental lactogen release from human placental tissue. A novel action of high density lipoprotein apolipoproteins. S Handwerger, … , J Barrett, I Harman J Clin Invest. 1987;79(2):625-628. https://doi.org/10.1172/JCI112857. Research Article High density lipoproteins (HDL) stimulated a dose-dependent increase in the release of placental lactogen (hPL) from human placental explants. The stimulation was not prevented by delipidation of HDL but was completely blocked by tryptic digestion. Delipidated apolipoproteins (Apo) AI, AII, and CI also stimulated hPL release but other apolipoproteins were without effect. HDL and Apo CI had no effects on the release of luteinizing hormone and follicle-stimulating hormone from rat pituitary cells or the release of prolactin from human decidual cells. Because placental cells have specific HDL receptors and plasma HDL concentrations increase during pregnancy, these results strongly suggest a role for HDL in the regulation of hPL release during pregnancy possibly independent of their usual role in plasma lipid transport. Find the latest version: https://jci.me/112857/pdf Rapid Publication Apolipoproteins Al, All, and Cl Stimulate Placental Lactogen Release from Human Placental Tissue A Novel Action of High Density Lipoprotein Apolipoproteins S. Handwerger, S. Quarfordt, J. Barrett, and 1. Harman Departments of Pediatrics, Physiology, and Medicine, Duke University Medical Center, Durham, North Carolina 27710 Abstract hPL are poorly understood. Because both plasma HDL (7-9) and hPL (4) concentrations increase progressively during preg- High density lipoproteins (HDL) stimulated a dose-dependent nancy, we have examined whether HDL stimulates the release increase in the release of placental lactogen (hPL) from human of hPL from human placental explants.
    [Show full text]